AUTHOR=Ma Chenzhe , Wang Xiao , Guo Jiwu , Yang Bo , Li Yumin 

TITLE=Challenges and future of HER2-positive gastric cancer therapy

JOURNAL=Frontiers in Oncology

VOLUME=13

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1080990

DOI=10.3389/fonc.2023.1080990

ISSN=2234-943X

ABSTRACT=<p>Gastric cancer is the fifth most common cancer worldwide, and the treatment of advanced gastric cancer has relatively little progress. With the continuous development of molecularly targeted therapy for tumors, it has been discovered that human epidermal growth factor receptor 2 (HER2) contributes to the poor prognosis and pathogenesis of various cancers. In order to treat HER2-positive advanced gastric cancer, Trastuzumab has emerged as the first first-line targeted medication used in conjunction with chemotherapy. The consequent trastuzumab resistance has become an important issue, and various new HER2-targeted gastric cancer drugs are emerging to address this challenge. This review’s primary concern is the drug mechanism of various HER2-positive gastric cancer targeted therapy and fresh techniques of detection.</p>